Great Basin Corporation Opens New, Expanded Manufacturing Facility to Meet Market Demand for Low-Cost, Easy-to-Use Molecular

  Great Basin Corporation Opens New, Expanded Manufacturing Facility to Meet
  Market Demand for Low-Cost, Easy-to-Use Molecular Diagnostics Tests

         Company Also Augments Staff with Sales and Support Personnel

Business Wire

SALT LAKE CITY -- November 13, 2012

Great Basin Corporation, a privately-held molecular diagnostics company
developing sample-to-result solutions, today announced the opening of a new
manufacturing facility. Dedicated to the manufacture of the company’s
closed-system molecular diagnostics cartridges, the facility more than triples
the company’s manufacturing capacity and is located adjacent to Great Basin’s
administrative and R&D facility in Salt Lake City. Currently, the company is
in full production manufacturing Clostridium difficile (C. diff) molecular
diagnostic assay cards used in the company’s Portrait Analyzer. The new
facility offers expansion capabilities to support future manufacturing needs
for the company’s aggressive product roadmap of molecular assays to aid in the
diagnosis of other critical hospital- acquired infections.

The company received approval from the U.S. Food and Drug Administration (FDA)
for its first product, a molecular diagnostic test for C. diff, at the
beginning of May. In the five months following receipt of FDA clearance, the
company has exceeded both sales and customer acquisition targets.

“Great Basin is experiencing impressive early sales success with our C. diff
assay,” said Ryan Ashton, president and CEO of Great Basin Corporation. “Based
on the overwhelming demand for our platform, we believe there is a critical
need in the market for an information-rich and low-cost test platform that
offers a significantly simplified workflow. This new manufacturing facility
will allow us to quickly ramp-up production to meet growing demand while
delivering the high level of quality and customer service to which Great Basin
is committed.”

The company also announced the addition of key personnel to support sales and
project implementation objectives. New key hires recently added to the Great
Basin team include:

  *Lisa Weingartner, Regional Business Director, Southeast – Ms. Weingartner
    comes to Great Basin most recently from Lineagen where she held the
    position of Regional Business Director.At Lineagen, Weingartner finished
    2011 as the #1 Regional Business Director and continued to hold that #1
    ranking in 2012.Prior to Lineagen, Weingartner worked for Genoptix,
    Athena Diagnostics, Specialty Labs, and Myriad Genetics.Weingartner will
    be directing Great Basin’s US commercialization efforts in the Southeast
    region.
  *Richard Corbiel, Applications Specialist. Mr. Corbiel comes to Great Basin
    most recently from BD Diagnostics where he managed their team of Molecular
    Client Consultants. In this role Corbiel coordinated field trainings and
    sales support for the U.S.Prior to his work at BD, Corbiel held similar
    positions at GeneOhm Sciences, Biomerieux and Gen-Probe. At Great Basin,
    Corbiel will be responsible for client implementation, training and
    support to assure client success.

The company intends to begin clinical trials for its Staph ID/R assay in early
2013. Its automated DNA multiplex assay can identify major pathogenic strains
of Staphylococcus to the species level as well as the presence or absence of
the methicillin-resistance determinant gene, mecA. Once the clinical trials
are completed, the company anticipates FDA clearance and CE-IVD product
marketing in Q2 of 2013.

About Great Basin Corporation

Great Basin Corporation is a privately-held molecular diagnostics company that
commercializes breakthrough chip-based technologies. The company is dedicated
to the development of simple, yet powerful, sample-to-result technology and
products that provide fast, multiple-pathogen diagnoses of infectious
diseases. By providing more diagnostic data per sample, healthcare providers
are able to treat patients with the right medication sooner, improving
outcomes and reducing costs. The company’s vision is to make molecular
diagnostic testing so simple and cost-effective that every patient will be
tested for every serious infection, reducing misdiagnoses and significantly
limiting the spread of infectious disease. More information can be found on
the company’s website at www.gbscience.com.

Contact:

Great Basin Corporation
Sandra Nielsen, 801-990-1055
snielsen@gbscience.com
or
Edelman
Jennifer Chan, 415-229-7650
jennifer.chan@edelman.com